Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

To join this study, you would need to have a specific type of advanced non-small cell lung cancer that has been confirmed by tests. This means your cancer would be considered advanced or have spread, and surgery or strong radiation treatment isn't an option. Your cancer must not have certain genetic changes that other specific drugs target, and it needs to show a high level of a marker called PD-L1 (meaning 50% or more of your cancer cells have it).

You must be at least 18 years old and in generally good health, typically able to do most everyday activities without much trouble. Doctors will also check your organ function and ensure you have suitable cancer sites that can be measured during the study.

There are also reasons why you might not be able to join. For example, if you've already had systemic treatment for your advanced lung cancer, or if your lung cancer is a different type (like small cell lung cancer or squamous cell dominant). People with certain other medical conditions, like some autoimmune diseases, or serious lung problems, might also not be suitable. Your doctor will carefully review all your medical information to see if this study is right for you.

If you join this study, you'll receive one of the study treatments (Dato-DXd with rilvegostomig, rilvegostomig alone, or pembrolizumab). You won't get to choose which one you receive; it's decided by chance, like flipping a coin. You'll have regular hospital visits for treatments, blood tests, scans, and check-ups to see how you're responding and to monitor any side effects. The study will last for a period while you are benefiting from the treatment or until your cancer progresses or you experience side effects that make it necessary to stop. After stopping treatment, you will continue to have follow-up appointments, typically for several years, to track your health and long-term outcomes. The total duration of your participation could vary, from several months to several years if you continue to do well.